Novo Nordisk(US:NVO) Globenewswireยท2025-09-08 14:28Core Points - A securities fraud class action lawsuit has been filed against Novo Nordisk A/S, alleging misrepresentations regarding the company's growth potential related to its diabetes/obesity drug, GLP-1 [3]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the District of New Jersey on behalf of investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Novo and certain senior officers [3]. Group 2: Legal Process - Investors wishing to serve as lead plaintiffs must file necessary documents by September 30, 2025 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [5].